Trials / Terminated

TerminatedNCT05194072

A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors

A Phase 1 Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors

Status: Terminated
Phase: Phase 1
Study type: Interventional
Enrollment: 250 (actual)

Sponsor: Seagen, a wholly owned subsidiary of Pfizer · Industry
Sex: All
Age: 18 Years
Healthy volunteers: Not accepted

Summary

The purpose of the study is to test the safety of the medicine called Felmetatug Vedotin alone and with pembrolizumab in participants with solid tumors. It will also look at the side effects of this medicine. A side effect is anything a medicine does to the body besides treating the disease. This study is seeking for participants who either have cancer: * that has spread in the body near where it started (locally advanced) and cannot be removed (unresectable), * has spread through the body (metastatic), or have some cancer left over after surgery. This study will have five parts. * Parts A and B of the study will find out how much Felmetatug Vedotin should be given to participants. * Part C will use the amount found in Parts A and B to find out how safe Felmetatug Vedotin is and if it works to treat solid tumor cancers. * Part D will find out if and how much Felmetatug Vedotin can be given with pembrolizumab. * Part E will use the amount found in Part D to find out how safe Felmetatug Vedotin with pembrolizumab is and if it works to treat triple negative breast cancer.

Conditions

Interventions

Type	Name	Description
DRUG	Felmetatug Vedotin	Given into the vein (IV; intravenously)
DRUG	Pembrolizumab	400 mg every 6 weeks, given by IV

Timeline

Start date: 2022-01-12
Primary completion: 2025-05-14
Completion: 2025-05-14
First posted: 2022-01-18
Last updated: 2026-01-09

Locations

27 sites across 5 countries: United States, Canada, Germany, Spain, United Kingdom

Regulatory

FDA-regulated drug study

Source: ClinicalTrials.gov record NCT05194072. Inclusion in this directory is not an endorsement.